NSW Health Commercialisation Training Program - Info Sessions

Commercialisation Crossroads

New South Wales is intensifying its focus on health innovation following the May 2025 release of the NSW Health Research and Innovation Strategy 2025-2030. This five-year plan aims to build a thriving ecosystem that turns research into marketable products, boosting both health outcomes and economic growth. The strategy emphasizes strategic investments, open access to assets like data and infrastructure, and a pipeline from discovery to commercialization. It builds on over a decade of state funding, positioning NSW as Australia's premier hub for medical research and tech development.

The Commercialisation Training Program, initiated in 2014, has been pivotal in this landscape. Originally focused on medical devices, it expanded its scope around 2021 to include diagnostics, therapeutics, and software as medical devices. A 2025 evaluation by the Office for Health and Medical Research quantified its success: over the past two years, alumni founded 23 companies, attracted $30.4 million in private investment and $124.9 million in grants, generated patents valued at $4.48 million, and created over 140 jobs. The program's total cost from 2014 to 2024 was $7.86 million, yielding a return of $20.53 per dollar spent. This data highlights its role in addressing a key barrier—lack of commercial skills among researchers and clinicians—amid Australia's push for manufacturing sovereignty post-pandemic.

Stakeholders include researchers, startups, hospitals, and investors across NSW. The program's impact extends to patients through faster deployment of innovations like advanced diagnostics and therapeutics, potentially reducing healthcare costs and improving access in regional areas. Deadlines loom large: the current contract extends only to mid-2026, with a tender for the next four years closing on January 30, 2026. Missing this window could disrupt ongoing courses starting in March 2026, costing momentum in a sector where delays mean lost opportunities to competitors like Victoria or Queensland.

Non-obvious tensions arise in balancing public funding with private gains. While the program is free to participants, it funnels talent toward profitable ventures, potentially diverting resources from pure public health research. There's also a risk of over-reliance on government support; the high ROI invites scrutiny on whether subsidies crowd out private training providers. Surprising data from the evaluation shows NSW perceived as Australia's strongest state for health tech commercialization, yet only 10% of program alumni secure major funding within a year, revealing the high failure rate in this field. Broader economic pressures, including inflation in R&D costs and global supply chain vulnerabilities, amplify the urgency: inaction could see NSW's $5 billion annual health research investment yield fewer tangible benefits.